Sp1高表达与脑膜瘤复发相关
该研究通过免疫组化染色检测74例脑膜瘤患者样本中Sp1的表达,分析其与临床病理参数的关系。结果显示Sp1表达与WHO分级、恶性程度及复发显著相关,Sp1高表达患者无复发生存时间较差,提示Sp1可能作为脑膜瘤预后生物标志物和治疗靶点。
要点
- Sp1表达与脑膜瘤WHO分级、恶性程度和复发显著相关
- Sp1高表达提示无复发生存时间较差
- Sp1可能成为脑膜瘤预后标志物和治疗靶点
核心结论
- 脑膜瘤患者中Sp1高表达与无复发生存时间较差相关,Sp1可能是预后生物标志物和治疗靶点。
研究设计与样本
- 回顾性收集2008至2012年高雄医学大学医院74例脑膜瘤患者样本,采用免疫组化染色检测Sp1表达并分析其与临床病理参数的关系。
主要发现
- Sp1表达与脑膜瘤患者WHO分级、恶性程度及复发显著相关。
- Sp1高表达患者无复发生存时间较差。
临床怎么用
- Sp1免疫组化检测或可辅助评估脑膜瘤复发风险,但尚需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningioma has the second highest incidence among primary intracranial tumors. There is no effective treatment or targeted therapy for meningioma except excision and radiotherapy. Sp1 (specificity protein 1) is a transcription factor that regulates tumor growth, but the literature describing the relationship between Sp1 and meningioma is scarce. The purpose of this study was to investigate the relationship between Sp1 expression and the clinicopathological parameters in meningioma by immunohistochemical staining. METHODS: We collected samples from 74 patients from 2008-2012 in Kaohsiung Medical University Hospital, with staging and prognosis of the pathological section of the meningioma. RESULTS: Our results show that Sp1 expression was significantly associated with World Health Organization grade, malignancy, and recurrence in patients with meningioma. CONCLUSIONS: High expression of Sp1 in patients with meningioma was linked to poor prognosis of recurrence-free time. Therefore Sp1 may be a candidate biomarker of prognosis and therapy target in meningioma.
引用
- Liu PC, Lieu AS, Lin CJ, et al. High Expression of Sp1 is Associated with Recurrence of Meningioma. World Neurosurg. 2021. PMID: 33453428. doi:10.1016/j.wneu.2021.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。